Press Release

IQVIA Malaysia wins CRO of the Year by Clinical Research Malaysia

May 19, 2025

KUALA LUMPUR, MALAYSIA — May 19, 2025 — IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that IQVIA Malaysia has been honored with the prestigious CRO of the Year Award by Clinical Research Malaysia, presented by YAB Dato’ Seri Anwar Bin Ibrahim, Prime Minister of Malaysia, and YB Datuk Seri Haji Dr. Dzulkefly bin Ahmad, Minister of Health.

“We are proud of IQVIA’s longstanding work to help drive industry-sponsored clinical research in Malaysia,” says Benjamin Laverty, vice president of clinical operations in Southeast Asia, India, Australia and New Zealand. “Our mission is to accelerate innovation for a healthier world and this award celebrates the impact we are having on patients’ lives.”

This marks the eighth consecutive year IQVIA has been named CRO of the Year by Clinical Research Malaysia, demonstrating IQVIA’s deep expertise to deliver excellence in clinical research and its steadfast commitment to enhance patient outcomes globally.

Malaysia's R&D Landscape

The global clinical trials market size was valued at over USD $76 billion in 2024. It is projected to grow from USD 80.71 billion in 2025 to reach USD 132.05 billion by 2033, with a CAGR of 6.3%.

Malaysia has recorded 239 sponsored clinical research trials as of November 2024, contributing to over RM 330 million in Gross National Income in 2024, and close to RM 1.5 billion cumulatively since 2012. The country is on track to become a burgeoning hub for research and development in the region.

IQVIA Malaysia is equipped with a robust set of expertise, offering a full spectrum of clinical and commercial solutions for biopharmaceutical, medical device and other healthcare and life science companies.

For more information, please contact IQVIA.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

Media Contacts

IQVIA:

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558

Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785

Contact Us